These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20133820)

  • 1. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
    Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
    Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
    Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
    Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
    Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
    Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
    Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of the MMP/TIMP Proteolytic System in Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex: Modulation of MMP by MicroRNA-320d In Vitro.
    Bongaarts A; de Jong JM; Broekaart DWM; van Scheppingen J; Anink JJ; Mijnsbergen C; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Hainfellner JA; Feucht M; Borkowska J; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Scicluna BP; Schouten-van Meeteren AYN; van Vliet EA; Mühlebner A; Mills JD; Aronica E
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):777-790. PubMed ID: 32472129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
    Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
    Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S; Hawkins C; Taylor MD; Bartels U
    Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures.
    Kuzniewska B; Sadowski K; Urbanska K; Urbanska M; Kotulska K; Liszewska E; Grajkowska W; Jóźwiak S; Dziembowska M
    Folia Neuropathol; 2018; 56(3):167-174. PubMed ID: 30509037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of microRNAs miR21, miR146a, and miR155 in tuberous sclerosis complex cortical tubers and their regulation in human astrocytes and SEGA-derived cell cultures.
    van Scheppingen J; Iyer AM; Prabowo AS; Mühlebner A; Anink JJ; Scholl T; Feucht M; Jansen FE; Spliet WG; Krsek P; Zamecnik J; Buccoliero AM; Giordano F; Genitori L; Kotulska K; Jozwiak S; Jaworski J; Liszewska E; van Vliet EA; Aronica E
    Glia; 2016 Jun; 64(6):1066-82. PubMed ID: 27014996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
    J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct DNA Methylation Patterns of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex.
    Bongaarts A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Coras R; Blümcke I; Paulus W; Gruber VE; Scholl T; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Söylemezoğlu F; Pimentel J; Jones DTW; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
    Cell Mol Neurobiol; 2022 Nov; 42(8):2863-2892. PubMed ID: 34709498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
    Tang X; Angst G; Haas M; Yang F; Wang C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
    Ichikawa T; Niida Y
    No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular therapies for tuberous sclerosis and neurofibromatosis.
    Franz DN; Weiss BD
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):294-301. PubMed ID: 22544507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex -  pharmacological treatment using mTOR inhibitors].
    Zitterbart K
    Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
    Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ
    Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.